EVUSHELD 150mg+150mg solution for injection ASTRAZENECA ORIGINAL MEDICINE
Chemical substance: tixagevimab + cilgavimab
ATC code: J06BD03 • Antiinfectives for systemic use | Immunoglobulins | Antiviral monoclonal antibodies
Active substance
Results for the substance tixagevimab+cilgavimab
1 result
About this active substance
Tixagevimab and cilgavimab are monoclonal antibodies used together for the prevention of COVID-19 in individuals at high risk of developing severe disease or who cannot be vaccinated. These antibodies work by binding to the spike protein of the SARS-CoV-2 virus, preventing it from entering human cells.
The medication is administered via intramuscular injection, usually in two separate doses, as directed by a doctor. It is used as a preventive measure and not as a treatment for active SARS-CoV-2 infections.
Patients should be monitored for potential side effects, such as allergic reactions, injection site pain, or flu-like symptoms. It is important for patients to inform their doctor of any unusual symptoms.
Common side effects include injection site pain, fatigue, headache, and fever. In rare cases, severe allergic reactions such as anaphylaxis may occur. Patients should be informed of these risks before administration.
The medication is administered via intramuscular injection, usually in two separate doses, as directed by a doctor. It is used as a preventive measure and not as a treatment for active SARS-CoV-2 infections.
Patients should be monitored for potential side effects, such as allergic reactions, injection site pain, or flu-like symptoms. It is important for patients to inform their doctor of any unusual symptoms.
Common side effects include injection site pain, fatigue, headache, and fever. In rare cases, severe allergic reactions such as anaphylaxis may occur. Patients should be informed of these risks before administration.